Fibrogen, Inc. Securities Litigation

Fibrogen, Inc. is a biopharmaceutical company that develops medicines for the treatment of anemia, fibrotic disease, and cancer. Its most advanced product is roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylase (“HIF-PH”) activity that acts by stimulating the body’s natural pathway for red cell production. In 2019, the Company filed its New Drug Application (“NDA”) with the U.S. Food and Drug Administration for the approval of roxadustat for the treatment of anemia due to chronic kidney disease (“CKD”).

See Case Details »

Champignon Brands Inc. Securities Litigation

Champignon Brands Inc. purports to be engaged in the formulation and manufacturing of novel ketamine, ketamine derivatives and other psychedelics, and delivery platforms for nutraceutical and psychedelic medicine while being supported by its psychedelic medicine clinic platform.

See Case Details »

Ebang International Holdings Inc. Securities Litigation

Ebang International Holdings Inc. purports to be a leading ASIC chip design company and a leading manufacturer of Bitcoin mining machines.

See Case Details »

Amdocs Limited Securities Litigation (2021)

Amdocs Limited, through its global subsidiaries, provides software and services to communications, cable and satellite, entertainment, and media industry service providers worldwide. Historically, the Company’s largest percentage of revenues come from its North American business, mostly the U.S., particularly from large customers including, among others, AT&T Inc.

See Case Details »

3D Systems Corp. Securities Litigation

3D Systems Corp. provides comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, on demand manufacturing services, and digital design tools.

See Case Details »